Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?

This study has been completed.
Information provided by:
Hvidovre University Hospital Identifier:
First received: June 30, 2005
Last updated: October 16, 2007
Last verified: October 2007

Post-ERCP pancreatitis can be a serious complication to ERCP. Two studies have shown a promising preventive effect of glyceryl nitrate. This study should provide a final answer to the clinical question: Does glyceryl nitrate prevent post-ERCP pancreatitis? The study is a prospective, randomized, double blind, placebo-controlled multicenter trial. The investigators intend to include 1600 patients from Norway, Sweden, Denmark, and France.

The patients will receive either placebo or a glyceryl nitrate patch (15 mg/24 hours). Follow-up will occur after 7 days. The primary outcome measure will be post-ERCP pancreatitis, and secondary outcome measures will be mild, moderate and severe pancreatitis; post procedure pancreatitis-related mortality; and adverse events.

Condition Intervention Phase
Drug: glyceryl nitrate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • acute pancreatitis within 7 days after the ERCP procedure. (An independent committee at each center will retrospectively judge whether patients have had post-ERCP pancreatitis or not in respect to a specific definition.)

Secondary Outcome Measures:
  • mild, moderate, and severe pancreatitis as a criterion proposed by Cotton et al [12]
  • post procedure pancreatitis-related mortality
  • adverse events (severe and non-severe such as headache, dizziness, hypotension, hypersensibility, and others)

Estimated Enrollment: 1600
Study Start Date: October 2004
Study Completion Date: October 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients (men and women) more than 18 years old who are going to have an ERCP procedure performed at the different centers from September 1, 2004 to about January 31, 2005 will be included.

Exclusion Criteria:

  • Before the study: active acute pancreatitis (defined as: acute upper abdominal pain and S-amylases x 3 upper normal limit OR upper abdominal pain + radiological findings [CAT-/MR-scan] consistent with acute pancreatitis OR pathoanatomical findings consistent with acute pancreatitis by surgery)
  • Known previous sphincterotomy
  • Chronic pancreatitis with known calcifications
  • Hypotension (definition: systolic blood pressure < 100 mmHg)
  • Anemia, men/women (hemoglobin < 6 mmol/l or <9.7 g/dl)
  • Constrictive pericarditis
  • Pericardial tamponade
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis
  • Mitral stenosis sildenafil within 24 hours before the ERCP procedure and 24 hours after the procedure
  • Hypersensibility to nitroglycerine
  • Hypersensibility to the applied glue on the patch
  • Known untreated hypothyroidism
  • Pregnancy or a potential to become pregnant, i.e. those who are not using safe contraception (intrauterine device [IUD] or oral contraception)
  • Included earlier in the study
  • Exchange of stent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00121901

Department of Medical and Surgical Gastroenterology, KAS Glostrup
Copenhagen, Glostrup, Denmark, 2600
Dept. of Medical Gastroenterology F, KAS Gentofte
Copenhagen, Hellerup, Denmark, 2900
Gastroenheden, Hvidovre Hospital
Copenhagen, Hvidovre, Denmark, 2650
Copenhagen, København Ø, Denmark, 2100
Køge County Hospital
Køge, Denmark, 4600
Dept of Medical Gastroenterology S, Odense Universitetshospital
Odense, Denmark, 5000
Serv Gastroenterologie Hopital Sainte Marguerite
Marseille, Marseille Cedex 09, France, F-13274
North Hospital
Marseille, France
Div of Gastroenterology, dept. of Int Medicine Affiliated Hospital University of Oslo, Østfold Fredrikstad
Fredrikstad, Norway, N-1603
Helse Fonna HF Haugesund Sjukehus Kirurgisk - vest blokk gastro
Haugesund, Norway, 5504
Ullevål Hospital
Oslo, Norway
Stavanger Hospital
Stavanger, Norway
Halmstad Hospital
Halmstad, Sweden
Dept of Surgery, University Hospital Malmö
Malmö, Sweden, S-205 02
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Camilla Nøjgaard Nøjgaard, MD Gastroenheden, Hvidovre Hospital, Kettegård Alle 30, 2650 Hvidovre
  More Information


Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00121901     History of Changes
Other Study ID Numbers: EPEPPS-06-2005
Study First Received: June 30, 2005
Last Updated: October 16, 2007

Keywords provided by Hvidovre University Hospital:
Cholangiopancreatograpy, Endoscopic Retrograde/adverse
Randomized Controlled Trial,

Additional relevant MeSH terms:
Pancreatic Diseases
Digestive System Diseases processed this record on April 24, 2017